Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Exclusive-EU to decide on Pfizer booster on Oct. 4 – document

by Wanda Rich
0 comment

By Francesco Guarascio and Emilio Parodi

BRUSSELS (Reuters) – The EU’s drugs regulator will decide on Monday whether to approve Pfizer’s COVID-19 booster vaccine, but it is unlikely to give precise guidance on who should receive it, according to an internal document and two officials.

If the European Medicines Agency (EMA) gives its backing for the jab, the 27-member block would join the United States, Britain and Israel which have already received the green light to deploy boosters, even though there is no consensus among scientists that they are necessary.

“On 4 October the EMA will deliver an opinion on the need for Pfizer boosters for the general population,” EMA’s head Emer Cooke told EU lawmakers in an internal meeting on Tuesday, according to minutes of the discussion seen by Reuters.

EMA was not immediately available for a comment.

EMA has publicly said it would decide on Pfizer’s booster at the start of October, but has never given a precise date.

More than a dozen EU countries have already started administering boosters without official EMA backing.

Official approval will provide legal protection to those countries and may spur others to launch a booster programme to fight the more infectious Delta variant during the winter months.

Two EU officials familiar with EMA’s decision-making processes said next week’s decision will focus on the booster’s safety and effectiveness, and will be broad in scope, meaning that it will not indicate precisely which age or risk groups should receive it.

That would be in line with EMA’s decisions on vaccine boosters for other diseases, such as tetanus.

The approach would also be consistent with EMA’s earlier decisions in the pandemic – for instance it largely left it up to member states to decide whether to restrict vaccines in the face of potential side effects.

The broad guidance would allow states to tailor the use of boosters to their national needs, without risking administering them beyond the instructions authorised by EMA – which would increase their legal risks.

In August, EMA said there was not enough data to recommend using boosters, and the World Health Organization has called for a halt to boosters until more people around the world have been vaccinated.

“There is no need of boosters for the general population, but there is some waning effect, especially for the elderly,” Cooke told EU legislators, according to minutes of Tuesday’s internal meeting.

The wide guidance could amplify differences across EU states. Who gets a booster in the region is already fragmented. In Austria, Hungary and the Czech Republic, authorities are aiming for wider rollouts, whereas in other states only some more vulnerable people would receive boosters.

The EU Commission has repeatedly warned that different national policies on vaccines can increase hesitancy.

The EMA’s broad approach would also differ from other major Western countries.

The U.S. Food and Drug Administration (FDA) last week recommended the Pfizer booster for those 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the virus.

In the United Kingdom, boosters are being given to all adults aged 50 years or over, healthcare workers, and all those at high risk from COVID-19 or in close contact with immuno-suppressed individuals.


Scientists are divided over whether boosters are needed, because it is not yet completely clear how long protection lasts in people who have been fully vaccinated, the European Centre for Disease prevention and Control (ECDC) said.

However, EU states have already bought additional vaccines for boosters.

They agreed in May to buy at least 900 million doses of the Pfizer and BioNTech vaccine. This came after the EU had already secured more than enough shots for its entire population from Pfizer and other vaccine makers.

Under the contract, EU governments are required to buy the 900 million shots mostly from next year, and could order another 900 million until 2023.

Given that nearly 75% of the EU’s adult population has already been fully vaccinated, most of the additional Pfizer doses would likely be needed only if administered as boosters.

An alternative would be to donate or sell them to poorer nations who have not yet got enough doses. Some of the vaccines could also be deployed on children or be used against potential new variants. Pfizer has agreed to sell the EU modified shots if needed.

But the decision on when a new variant may be predominant and whether the existing vaccine is not effective against it requires a complex procedure which makes it difficult to force Pfizer to provide an updated version, two people familiar with the contract told Reuters.

Pfizer had no comment on the contract with the EU but the company’s boss Albert Bourla has said that it can develop in less than 100 days updated versions of its COVID-19 vaccine, if new variants emerged.

(Reporting by Francesco Guarascio @fraguarascio and Emilio Parodi;Editing by Josephine Mason, Elaine Hardcastle)